HIV Drug Resistance Database
HIV耐药数据库
基本信息
- 批准号:9921291
- 负责人:
- 金额:$ 88.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-05-01 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS clinical trial groupAcquired Immunodeficiency SyndromeAddressAnti-Retroviral AgentsAntiviral AgentsBotswanaCaliforniaCatalogsCenters for Disease Control and Prevention (U.S.)ClientClinicalClinical DataClinical ManagementClinical ResearchClinical TrialsCodeCohort StudiesCollaborationsCommunitiesComputer softwareDataData SetDatabasesDevelopmentDrug CombinationsDrug resistanceEpidemiologyFailureFeedbackFutureGeneticGenotypeGeographic LocationsGuidelinesHIVHIV drug resistanceHIV therapyHIV-2HealthIntegraseInternationalKenyaKnowledgeLaboratoriesLaboratory ResearchLiteratureManagement Information SystemsMedical ResearchMethodsMolecularMolecular TargetMonitorMutationNational Health ServicesOutcomePatientsPeptide HydrolasesPersonsPharmaceutical PreparationsPharmacotherapyPrevalencePreventionPublic HealthPublished CommentPublishingRNA-Directed DNA PolymeraseRecording of previous eventsRegimenResearchResearch InstituteResearch PersonnelResearch SupportResistanceResourcesSequence AnalysisSouth AfricaStandardizationTestingUnited States National Institutes of HealthUpdateVirusWorkantiretroviral therapybasecombatdesigndrug developmentepidemiology studyhigh riskimprovedknowledge basenext generation sequencingnovelopen sourcepandemic diseasephenotypic datapopulation basedpredicting responseprogramsrecruitresistance mutationresistant strainsuccesstoolvirologyweb site
项目摘要
PROJECT SUMMARY
HIV drug resistance (HIVDR) is a threat to the success of antiretroviral therapy (ART) and a major barrier to
the elimination of AIDS as a public health problem. Persons with HIV who develop virological failure during
ART are at high risk of developing HIVDR and possibly transmitting a drug-resistant strain to others, and
persons who are infected with a drug-resistant HIV strain are at high risk of developing virological failure.
Comprehensive, accurate, and publicly available HIVDR data are essential for population-based monitoring
of acquired and transmitted HIVDR, for the clinical management of HIV-infected patients, and for identifying
overall drug-development needs. A public database that curates, annotates, and disseminates the primary
data from HIVDR studies will make it possible to identify and characterize the HIVDR mutations most
relevant to surveillance, clinical management, and drug development, and it will expedite research into the
mechanisms of HIVDR and the predictors of response to the newest ARV regimens.
The Stanford HIV Drug Resistance Database (HIVDB) has provided a unique conceptual framework for
addressing data-intensive questions about the main molecular targets of HIV therapy: reverse transcriptase,
protease, and integrase. HIVDB’s sequence analysis programs have also become integrated into the
workflows of many research laboratories worldwide. This Research Resource project is designed to improve
HIVDB by (i) replacing the previous ad hoc approach to data recruitment with a sustainable systematized
approach; (ii) streamlining and automating many of its core functions; (iii) expanding the user base to target
the most pressing global HIVDR research questions; and (iv) establishing principles of governance for the
inclusion of data in HIVDB and access to data in HIVDB.
Specific Aims: (1) To create a sustainable resource that catalogs the extent and genetic mechanisms of
acquired and transmitted HIVDR. Accomplishing this aim will enable researchers to identify gaps in the
published literature, perform novel analyses, and discover new knowledge; (2) To regularly update the
knowledge base required for interpreting HIV genotypic resistance tests and other online HIVDR analyses.
Accomplishing this aim will establish standards that can be applied to the analysis of HIVDR data across the
many molecular epidemiological and clinical studies performed each year; and (3) To provide enhanced
support for national and international research collaborations by creating improved software clients and
APIs for accessing HIVDB and new open-source software for analyzing HIVDR data. Accomplishing this
aim will support researchers in using HIVDB to advance their research, promote public availability of data
from new HIVDR studies, and generate feedback to be used in developing additional HIVDR research tools.
项目摘要
HIV耐药性(HIV drug resistance,HIV DR)是抗逆转录病毒治疗(antiretroviral therapy,ART)成功的威胁,也是HIV感染的主要障碍。
消除艾滋病这一公共卫生问题。感染艾滋病毒的人,
抗逆转录病毒疗法有很高的风险发展成艾滋病,并可能将耐药菌株传播给他人,
感染耐药HIV毒株的人有很高的风险发生病毒学失败。
全面、准确和公开的艾滋病毒/艾滋病数据对基于人口的监测至关重要
获得性和传播的HIV感染者,用于HIV感染患者的临床管理,
药物开发的总体需求。一个公共数据库,用于管理、注释和传播
来自HIV研究的数据将使识别和表征HIV突变成为可能,
与监测、临床管理和药物开发有关,它将加快对
艾滋病的机制和对最新抗逆转录病毒治疗方案反应的预测因素。
斯坦福大学艾滋病毒耐药性数据库(HIV DB)提供了一个独特的概念框架,
解决有关HIV治疗的主要分子靶点的数据密集型问题:逆转录酶,
蛋白酶和整合酶。HIV数据库的序列分析程序也已整合到
全球许多研究实验室的工作流程。该研究资源项目旨在提高
㈠以可持续的系统化方法取代以前的临时数据收集方法,
(二)加强了信息系统的管理;(三)加强了信息系统的管理;(四)加强了信息系统的管理;(五)加强了信息系统的管理;(六)加强了信息系统的管理;
最紧迫的全球艾滋病毒/艾滋病研究问题;以及(iv)建立
将数据纳入艾滋病毒数据库和获取艾滋病毒数据库中的数据。
具体目标:(1)创建一个可持续的资源,目录的程度和遗传机制,
获得并传播艾滋病病毒。实现这一目标将使研究人员能够确定
发表文献,进行新的分析,发现新的知识;(2)定期更新
解释HIV基因型耐药性测试和其他在线HIV DR分析所需的知识基础。
实现这一目标将建立可用于分析全球艾滋病毒/艾滋病数据的标准。
每年进行多项分子流行病学及临床研究;及(3)加强
通过创建改进的软件客户端支持国家和国际研究合作,
访问HIV数据库的API和分析HIV数据的新开源软件。完成这一
aim将支持研究人员使用HIV数据库来推进他们的研究,促进数据的公开可用性,
从新的艾滋病毒/艾滋病研究中,并产生反馈,用于开发更多的艾滋病毒/艾滋病研究工具。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT William SHAFER其他文献
ROBERT William SHAFER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT William SHAFER', 18)}}的其他基金
HIV-1 Leader Mutations During RT Inhibitor Therapy
RT 抑制剂治疗期间的 HIV-1 领导突变
- 批准号:
9981647 - 财政年份:2019
- 资助金额:
$ 88.38万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 88.38万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 88.38万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 88.38万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 88.38万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 88.38万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 88.38万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 88.38万 - 项目类别: